CD20 Antibody-Drug Conjugate With Controlled DAR Distribution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates targeting CD20 have inconsistent and unpredictable drug loading, leading to variations in efficacy, stability, toxicity, and manufacturing costs, without achieving optimal therapeutic effects.
Innovation Solution
Development of an antibody-drug conjugate with a specific DAR component distribution, optimized through controlled feed ratios, using a linker and sulfhydryl group conjugating technology, resulting in a mixture of DAR values ranging from 3.98 to 4.66, with specific percentages for each DAR component, ensuring consistent drug loading and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing antibody-drug conjugates targeting CD20 are used, then tumor treatment is achieved, but drug loading is inconsistent and unpredictable, leading to variations in efficacy, stability, and toxicity
Solution Approach 1:
The patent applies parameter changes by optimizing the DAR (Drug-to-Antibody Ratio) to a specific range of 3.98-4.66 with controlled component distribution. This precise parameter control ensures consistent drug loading across batches, resolving the contradiction between manufacturing precision and efficacy reliability. The controlled feed ratio and specific DAR range transform the unpredictable drug loading into a consistent, controllable parameter.
Solution Approach 2:
The patent implements feedback control through quality testing methods that measure and verify the DAR value and component distribution. This feedback mechanism ensures that each batch meets the specified DAR range (3.98-4.66) and component percentage requirements, thereby guaranteeing consistent efficacy and stability while maintaining manufacturing precision.
2Object-affected harmful factors
If existing antibody-drug conjugates are used, then tumor treatment is achieved, but toxicity is increased due to inconsistent drug loading
Solution Approach 1:
The patent reduces toxicity by changing the DAR parameter to a controlled range of 3.98-4.66, avoiding both under-loading (insufficient efficacy) and over-loading (excessive toxicity). This precise parameter control ensures optimal drug loading that maximizes tumor cell killing while minimizing harmful effects on healthy cells.
Solution Approach 2:
The patent uses quality testing and component analysis to provide feedback on drug loading levels. This feedback system ensures that each batch falls within the optimal DAR range, preventing toxic over-loading while maintaining sufficient therapeutic loading, thereby resolving the contradiction between manufacturing precision and toxicity reduction.
3Ease of manufacture
If existing antibody-drug conjugates are used, then treatment is provided, but manufacturing costs vary due to inconsistent drug loading
Solution Approach 1:
The patent standardizes manufacturing by establishing a specific DAR range (3.98-4.66) and component distribution profile. This parameter standardization enables consistent drug loading across different batches, making manufacturing costs predictable and uniform, thereby resolving the contradiction between ease of manufacture and manufacturing precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The optimized antibody-drug conjugate demonstrates superior tumor cell killing efficacy, improved stability, and reduced toxicity, while maintaining clinical effectiveness and lowering manufacturing costs, as shown by in vitro and in vivo tests.
Implementation Method 1
using a linker and sulfhydryl group conjugating technology
Data Source
AI summary
Provided is a CD20-targeted antibody-drug conjugate and a pharmaceutical composition comprising thereof, as well a method for preparing the same. The antibody-drug conjugate of the present invention has a specific DAR component distribution optimized for drug loading, and is produced by accurately controlling the feed ratio. The antibody-drug conjugate of the present invention has excellent drug activity, good stability, low toxicity and good drug development properties.